810 related articles for article (PubMed ID: 19080989)
21. Methotrexate and ciclosporin combination for the treatment of severe psoriasis.
Aydin F; Canturk T; Senturk N; Turanli AY
Clin Exp Dermatol; 2006 Jul; 31(4):520-4. PubMed ID: 16716153
[TBL] [Abstract][Full Text] [Related]
22. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
Haitz KA; Kalb RE
J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
[TBL] [Abstract][Full Text] [Related]
23. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
Lecha M; Mirada A; López S; Artés M;
J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
[TBL] [Abstract][Full Text] [Related]
24. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).
Reich K; Wozel G; Zheng H; van Hoogstraten HJ; Flint L; Barker J
Br J Dermatol; 2013 Jun; 168(6):1325-34. PubMed ID: 23621698
[TBL] [Abstract][Full Text] [Related]
26. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
28. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
29. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
30. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice.
Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E
Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936
[TBL] [Abstract][Full Text] [Related]
31. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Balasubramaniam P; Stevenson O; Berth-Jones J
Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
[TBL] [Abstract][Full Text] [Related]
32. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
33. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR; Gottlieb AB; Bala M; Wu Y; Eisenberg D; Guzzo C; Li S; Dooley LT; Menter A
Br J Dermatol; 2008 Sep; 159(3):704-10. PubMed ID: 18627375
[TBL] [Abstract][Full Text] [Related]
34. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.
Reich K; Nestle FO; Wu Y; Bala M; Eisenberg D; Guzzo C; Li S; Dooley LT; Griffiths CE
Eur J Dermatol; 2007; 17(5):381-6. PubMed ID: 17673380
[TBL] [Abstract][Full Text] [Related]
35. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
36. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
38. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
39. Three years' experience with infliximab in recalcitrant psoriasis.
Ahmad K; Rogers S
Clin Exp Dermatol; 2006 Sep; 31(5):630-3. PubMed ID: 16901301
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena M; Katsambas A; Connors L; Chang Q; Yao R; Nograles K; Popmihajlov Z;
Br J Dermatol; 2014 Sep; 171(3):631-41. PubMed ID: 24673357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]